-
Article | 2024.04.30
Pierre Lépine, virus explorer
Known for discovering a poliomyelitis vaccine, this researcher with a keen interest in the history of medicine also furthered use of the microscope and worked on health for Paris City Council.
-
News | 2024.12.17
Does vaccination reduce the virulence of the bacteria responsible for whooping cough?
Following an analysis of bacterial samples from infants with whooping cough, scientists from the National Reference Center (CNR) for Whooping Cough and other Bordetellosis have revealed that the most severe forms of the disease are associated with specific strains expressing a key vaccine antigen. This discovery suggests that the bacteria may have evolved into less virulent and therefore less...
-
Document de presse | 2015.12.21
The mechanism of an AIDS vaccine candidate filmed in vivo
Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows how the vaccine recruits the immune cells needed to destroy infected cells. These results, published in the...
-
Document de presse | 2021.09.21
Covid-19: study on the effectiveness of immune memory after mRNA vaccination to recognize variants of SARS-CoV-2
The teams from Henri-Mondor AP-HP hospital and Paris-Est Créteil University, Inserm, CNRS, University of Paris, within the Necker-Enfants Malades Institute, and the Institut Pasteur analyzed the capacity of the immune memory generated after mRNA vaccination to recognize and neutralize SARS-CoV-2 variants.This work, coordinated by Prof. Matthieu Mahévas, Dr Claude-Agnès Reynaud, Prof. Jean-Claude...
-
Document de presse | 2022.12.19
Modelling has evaluated the role of antiviral treatment and vaccination in exiting the Zero-COVID strategy in Wallis and Futuna
By June 2022, the Wallis and Futuna Islands, a French overseas territory, had successfully implemented a Zero-COVID strategy that significantly reduced the number of SARS-CoV-2 infections. From mid-June 2022, a gradual reopening of the borders was planned. However, the relatively low immunity in the population (due to limited vaccination coverage and the number of previous infections) and the...
-
Document de presse | 2021.07.16
ComCor study: analysis of the effectiveness of messenger RNA vaccines against the SARS-CoV-2 Alpha and Beta variants in France
Over the past six months, the World Health Organization has categorized four SARS-CoV-2 variants as being "of concern" because they are more transmissible or may escape the immune response. They have been termed the Alpha, Beta, Gamma and Delta variants. Scientists from the Institut Pasteur, in collaboration with the French National Health Insurance Fund (CNAM), Ipsos and Santé publique France,...
-
Document de presse | 2021.11.26
ComCor study: new results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on circumstances and places of infection with the SARS-CoV-2 virus in France. The aim of the study was to identify the socio-demographic factors, places visited and...
-
News | 2021.09.30
An exceptional case of rabies in France transmitted by a bat
On rare occasions in mainland France, a bite or scratch by a bat can transmit a virus capable of causing rabies, as was the case for a patient in 2019. Experts from the National Reference Center for Rabies at the Institut Pasteur contributed to a study on that particular case this year, in cooperation with research teams from the Institut Pasteur and Necker Enfants Malades and Pitié-Salpêtrière...
-
Document de presse | 2023.06.06
Monkeypox: characterization of post-infectious immune response
In 2022-2023, an outbreak of monkeypox, now known as mpox (caused by the monkeypox virus or MPXV) led to 87,000 human cases in 170 countries[1]. Most cases were reported outside the usual areas in which the virus circulates. Since the outbreak began, surveillance of the virus has been stepped up in Europe, with nearly 5,000 cases being reported in France[2]. Scientists and clinicians from the...
-
Document de presse | 2021.12.23
COVID-19 – Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological studies show that the Omicron variant is more transmissible than the currently dominant virus (the Delta variant). It is capable of spreading to individuals who have received...